Cancers, Vol. 13, Pages 4580: Hyperthermic Intrathoracic Chemotherapy (HITOC) after Cytoreductive Surgery for Pleural Malignancies —A Retrospective, Multicentre Study

Cancers, Vol. 13, Pages 4580: Hyperthermic Intrathoracic Chemotherapy (HITOC) after Cytoreductive Surgery for Pleural Malignancies—A Retrospective, Multicentre Study Cancers doi: 10.3390/cancers13184580 Authors: Michael Ried Julia Kovács Till Markowiak Karolina Müller Gunnar Huppertz Michael Koller Hauke Winter Laura V. Klotz Rudolf Hatz Julia Zimmermann Bernward Passlick Severin Schmid Mohamed Hassan Martin E. Eichhorn Hans-Stefan Hofmann In the context of quality assurance, the objectives were to describe the surgical treatment and postoperative morbidity (particularly renal insufficiency). A retrospective, multicentre study of patients who underwent cytoreductive surgery (CRS) with cisplatin-based HITOC was performed. The study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation (GZ: RI 2905/3-1)). Patients (n = 350) with malignant pleural mesothelioma (n = 261; 75%) and thymic tumours with pleural spread (n = 58; 17%) or pleural metastases (n = 31; 9%) were analyzed. CRS was accomplished by pleurectomy/decortication (P/D: n = 77; 22%), extended P/D (eP/D: n = 263; 75%) or extrapleural pneumonectomy (EPP: n = 10; 3%). Patients received cisplatin alone (n = 212; 61%) or cisplatin plus doxorubicin (n = 138; 39%). Low-dose cisplatin (≤125 mg/m2 BSA) was given in 67% of patients (n = 234), and high-dose cisplatin (>125 mg/m2 BSA) was given in 33% of patients (n = 116). Postoperative renal insuf...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research